A 28 Week, Treatment Randomized, Double -Blind, Placebo-controlled Study of the Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA).
Phase of Trial: Phase II
Latest Information Update: 23 May 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms KIA
- 15 May 2017 Status changed from active, no longer recruiting to completed.
- 06 Mar 2017 Results of effects of imatinib on airway mast cells presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 13 Sep 2012 Planned End Date changed from 1 Apr 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.